Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
6.160
+0.130 (+2.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about C4 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
C4 Therapeutics's Return On Capital Employed Overview
November 23, 2022
Via
Benzinga
C4 Therapeutics: Q3 Earnings Insights
November 03, 2022
C4 Therapeutics (NASDAQ:CCCC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session
November 25, 2022
Gainers Peak Bio, Inc. (NYSE: PKBO) shares jumped 49.1% to $7.08.
Via
Benzinga
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points
November 25, 2022
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 100 points on Friday. Equity markets will close early on Black Friday, the day after Thanksgiving.
Via
Benzinga
Credit Suisse, Autodesk And Other Big Losers From Wednesday
November 25, 2022
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Recap: C4 Therapeutics Q2 Earnings
August 04, 2022
C4 Therapeutics (NASDAQ:CCCC) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
C4 Therapeutics: Q1 Earnings Insights
May 05, 2022
C4 Therapeutics (NASDAQ:CCCC) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Where C4 Therapeutics Stands With Analysts
April 28, 2022
Within the last quarter, C4 Therapeutics (NASDAQ:CCCC) has observed the following analyst ratings:
Via
Benzinga
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
November 25, 2022
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 24, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
November 04, 2022
Upgrades
Via
Benzinga
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 03, 2022
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
September 29, 2022
Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics's Return On Capital Employed Insights
August 22, 2022
According to Benzinga Pro data, during Q2, C4 Therapeutics (NASDAQ:CCCC) posted sales of $13.83 million. Earnings were up 13.31%, but C4 Therapeutics still reported an overall loss of $27.41 million.
Via
Benzinga
C4 Therapeutics's Return On Capital Employed Overview
May 27, 2022
C4 Therapeutics (NASDAQ:CCCC) brought in sales totaling $7.65 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 101.94%, resulting in a loss of $31.62 million.
Via
Benzinga
C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers
May 16, 2022
C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial...
Via
Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
September 19, 2022
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Via
Benzinga
66 Biggest Movers From Yesterday
May 03, 2022
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged...
Via
Benzinga
31 Stocks Moving In Monday's Mid-Day Session
May 02, 2022
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
April 28, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 19, 2022
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
BMO Capital Maintains Outperform Rating for C4 Therapeutics, Lowers Price Target To $20
April 11, 2022
BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics (NASDAQ:CCCC) and lower its price target from $57.00 to $20.00. Shares of C4 Therapeutics are trading down 20.49% over the...
Via
Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Via
Benzinga
Why C4 Therapeutics Stock Is Plunging Today
April 08, 2022
C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical...
Via
Benzinga
C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
April 08, 2022
C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL).
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 08, 2022
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.